Ladenburg Thalmann Financial Services’s CRISPR Therapeutics CRSP Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$953K	Buy	15,649 +3,104	+25%	+$169K	0.01%	1318
2019 Q3	$514K	Buy	12,545 +1,394	+13%	+$66.6K	﹤0.01%	1745
2019 Q2	$527K	Buy	11,151 +117	+1%	+$4.68K	﹤0.01%	1706
2019 Q1	$395K	Buy	11,034 +628	+6%	+$21.7K	﹤0.01%	1873
2018 Q4	$297K	Buy	10,406 +1,855	+22%	+$64.5K	﹤0.01%	1917
2018 Q3	$380K	Buy	8,551 +4,497	+111%	+$236K	﹤0.01%	1814
2018 Q2	$186K	Hold	4,054	–	–	﹤0.01%	2292
2018 Q1	$186K	Buy	4,054 +3,120	+334%	+$129K	﹤0.01%	2292
2017 Q4	$22K	Buy	934 +300	+47%	+$5.7K	﹤0.01%	3722
2017 Q3	$11K	Buy	634 +534	+534%	+$9.68K	﹤0.01%	4021
2017 Q2	$2K	Hold	100	–	–	﹤0.01%	4582
2017 Q1	$2K	Buy	+100	New	+$1.96K	﹤0.01%	4547

Other funds holding CRSP

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ladenburg Thalmann Financial Services's CRSP Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its CRISPR Therapeutics (CRSP) stake by 25% in Q4 2019, buying an estimated $169K and bringing the position to 15,649 shares worth $953K. The position accounts for 0.01% of the portfolio, ranked #1318.

Ladenburg Thalmann Financial Services first reported a position in CRSP in Q1 2017 and has held it in 12 quarters since. 253 funds tracked by Wall St. Rank hold CRSP as of Q4 2019.

Ladenburg Thalmann Financial Services held 15,649 shares of CRISPR Therapeutics worth $953K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 3,104 CRISPR Therapeutics shares in Q4 2019, an estimated $169K.
CRISPR Therapeutics made up 0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #1318 holding.
Ladenburg Thalmann Financial Services first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 12 quarters since.
253 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.